TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23813620
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 mg single dose
Study: 23813620
Drug: Isradipine 10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 10 mg single dose
Study: 23813620
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 mg multiple doses
Study: 17081163
Drug: Nitazoxanide 500
Normalized name: nitazoxanide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 500 mg twice daily for 3 days
Study: 15579757
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 or 8 mg/d) for 26 weeks
Study: 9422013
Drug: Medical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatments (n = 94)
Study: 8101550
Drug: HIV-immune plasma
Normalized name: IMMUNE GLOBULIN PLASMA BOVINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-immune plasma (250 mL every 4 weeks)
Study: 8101550
Drug: HIV antibody-negative
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV antibody-negative plasma (250 mL every 4 weeks)
Study: 3552925
Drug: Prednisolone therapy
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone therapy (28-day course)
Study: 30141288
Drug: EMG guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG guided point injection at Renying (ST 9), administered three times a week for 2 weeks, in addition to conventional drugs and rehabilitation training.
Study: 30141288
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs combined with rehabilitation training, administered once daily for 2 weeks.
Study: 23512320
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing intervention using smart scales and e-mail
Study: 18219456
Drug: Gout prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gout prescription I
Study: 18219456
Drug: Gout prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gout prescription II
Study: 18219456
Drug: Gout prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gout prescription III
Study: 12823646
Drug: Warfarin 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 1.25 mg + Aspirin 75 mg daily (W/A)
Study: 11905682
Drug: Radical prostatectomy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical prostatectomy, radical radiotherapy, and monitoring with treatment if required.
Study: 1464336
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of metoprolol
Study: 31486253
Drug: Low-dose tramadol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tramadol (0.5 mg/kg)
Study: 31486253
Drug: Meperidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (0.5 mg/kg and 0.75 mg/kg)
Study: 31486253
Drug: Fentanyl (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.5 mcg/kg and 0.75 mcg/kg)
Study: 29502373
Drug: Postoperative precision
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative precision nutrition treatment
Study: 29502373
Drug: Traditional postoperative
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional postoperative nutrition treatment
Study: 25251377
Drug: Zeaxanthin only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zeaxanthin only (20 mg/day; n=29)
Study: 25251377
Drug: Mixed formulation
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed formulation (26 mg/day zeaxanthin, 8 mg/day lutein, and 190 mg/day mixed omega‐3 fatty acids; n=25)
Study: 23158830
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care for the prevention and treatment of DM2 currently provided in Osakidetza
Study: 21061788
Drug: neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm; n = 159)
Study: 12691318
Drug: neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm)
Study: 17922895
Drug: r-hGH administered
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hGH administered by cool.click 2
Study: 17922895
Drug: r-hGH administered
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hGH administered by needle and syringe
Study: 16320942
Drug: Test sustained-release
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test sustained-release indapamide formulation (3 mg)
Study: 16320942
Drug: Reference sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference sustained-release indapamide formulation (3 mg)
Study: 11880565
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (ferrous sulfate 300 mg/tablet)
Study: 11880565
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (ferrous sulfate 300 mg/tablet)
Study: 7649495
Drug: Allopurinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (200 mg during induction of anesthesia and 100 mg after starting extracorporeal circulation)
Study: 2669552
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with dog or cat extract (n = 14), subcutaneous injections with alum-adsorbed depot extract (Alutard-SQ), maintenance dose of 100,000 SQ-U or maximum tolerated dose.
Study: 2669552
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical therapy (n = 13).
Study: 2669552
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with dog or cat extract (n = 14).
Study: 31146544
Drug: Erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 70 mg monthly (initial dosage)
Study: 28582403
Drug: Cholecalcipherol (300,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalcipherol (300,000 IU) combined with standard treatment (methotrexate and glucocorticoids)
Study: 28582403
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (methotrexate and glucocorticoids) without cholecalcipherol
Study: 23855643
Drug: Antibiotic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic regimen (pre- and post-operative)
Study: 23454858
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment of the medial malleolus
Study: 16764619
Drug: Laparoscopic ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic ovarian drilling (LOD) plus 1700 mg per day of metformin for 6 months
Study: 2758733
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of cimetidine (300 mg every 6 hours)
Study: 2758733
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cimetidine (37.5 mg per hour with a priming dose of 300 mg for 15 minutes)
Study: 28776062
Drug: Mindfulness practice
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness practice (20-min sessions weekly for one academic semester)
Study: 25871786
Drug: CASUS® group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CASUS® group (using online cases for preparation)
Study: 30502311
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (no noninvasive ventilation)
Study: 28859383
Drug: Sodium alginate
Normalized name: Sodium Alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium alginate (10 mL of Gaviscon Advance)
Study: 28859383
Drug: Water (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (10 mL)
Study: 25847503
Drug: Topical autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologous platelet-rich gel (APG) plus standard treatment
Study: 25847503
Drug: Topical APG
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical APG application
Study: 24080677
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy
Study: 21422207
Drug: Voriconazole 300
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole 300 mg
Study: 21422207
Drug: Voriconazole 200
Normalized name: voriconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 200 mg
Study: 12909380
Drug: CC-CPR training
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-CPR training (n=36)
Study: 10877011
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg single oral dose in healthy controls
Study: 10877011
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg single oral dose in malaria patients
Study: 10877011
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg single oral dose in both groups
Study: 10437215
Drug: Electro-acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture and routine treatment (Group 1, n = 29)
Study: 10437215
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment alone (Group 2, n = 30)
Study: 30549489
Drug: NAC +
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC + aspirin (1,000 mg each)
Study: 30549489
Drug: NAC (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC (1,000 mg)
Study: 20398037
Drug: MK-0429 200
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0429 200 mg b.i.d.
Study: 20398037
Drug: MK-0429 1600
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0429 1600 mg b.i.d.
Study: 23343466
Drug: Pre-exposure cream
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exposure cream
Study: 23343466
Drug: Post-exposure cream
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-exposure cream
Study: 23343466
Drug: Pre-exposure cream
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exposure cream + Post-exposure cream
Study: 21614939
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine approach (six group sessions on nutritional manipulation, yoga techniques, journaling, plus nutritional supplements: fish oil, vitamin C, standardized hops extract)
Study: 21614939
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine approach
Study: 19548250
Drug: CAMHS outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMHS outpatient treatment
Study: 20334748
Drug: Specialist outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialist outpatient treatment
Study: 9485979
Drug: Pre-operative administration
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative administration of bupivacaine
Study: 9485979
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of bupivacaine
Study: 8379174
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) retrograde injection
Study: 30839100
Drug: Cycle-Specific Risk
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle-Specific Risk of Febrile Neutropenia after Chemotherapy score (CSRFENCE score)
Study: 26879276
Drug: Ozanimod 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 1 mg
Study: 24474034
Drug: E2/LNG Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/LNG Low TDS (4.4 mg E2 and 1.39 mg LNG)
Study: 24474034
Drug: E2/LNG High
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/LNG High TDS (4.4 mg E2 and 2.75 mg LNG)
Study: 24474034
Drug: E2 0.050
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 0.050 mg/24 hours TDS and 0.090 mg LNG oral tablet
Study: 15638905
Drug: Doxazosin extended-release
Normalized name: doxazosin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin extended-release (XL) 4 or 8 mg once daily for 13 weeks
Study: 15638905
Drug: Doxazosin standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin standard 1-8 mg once daily for 13 weeks
Study: 11942178
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment (chemotherapy, radiotherapy, multimodal treatments)
Study: 10091516
Drug: Home intravenous
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home intravenous antibiotic therapy
Study: 10091516
Drug: Hospital intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital intravenous antibiotic therapy
Study: 31924257
Drug: Regular gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular gel or silicone liners for 6 months
Study: 31112620
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg twice/day
Study: 31112620
Drug: Lower than
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower than recommended dosing of apixaban
Study: 31112620
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg twice/day
Study: 31112620
Drug: Recommended dosing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dosing of 5 mg twice/day
Study: 27430990
Drug: Bupivacaine lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine lozenge (25 mg) administered as single dose to HNC patients with oral mucositis
Study: 27430990
Drug: Bupivacaine lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine lozenge (25 mg) administered as multiple doses to HNC patients with oral mucositis
Study: 27430990
Drug: Bupivacaine lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine lozenge (5, 10, 25, and 50 mg) administered as single dose to healthy individuals
Study: 18563473
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training combined with child therapy (PT + CT)
Study: 7523775
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg estradiol valerate
Study: 6363985
Drug: tiropramide hydrochloride
Normalized name: tiropramide hydrochloride
DrugBank: Tiropramide (DB13091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiropramide hydrochloride (300 mg daily for 30 days)
Study: 6363985
Drug: octylonium bromide
Normalized name: octylonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: octylonium bromide (120 mg daily)
Study: 27049275
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of magnesium sulfate
Study: 22350328
Drug: Mentha crispa
Normalized name: Mentha crispa oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentha crispa (24 mg)
Study: 22350328
Drug: Secnidazole (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secnidazole (2,000 mg)
Study: 17381122
Drug: Dried cranberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried cranberry juice (DCJ) 1200 mg/day
Study: 17381122
Drug: Dried cranberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried cranberry juice (DCJ) 400 mg/day
Study: 11049910
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluvoxamine and erythromycin
Study: 28748081
Drug: 225 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 μg iodine as potassium iodide capsule daily for 6 months
Study: 28748081
Drug: 450 g
Normalized name: IODINE 450 g in 10 L TOPICAL LIQUID [UDDERBLEND]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 g of appropriately iodized salt (30‐40 μg I as KIO3/g of salt) weekly for household consumption for 6 months
Study: 19218540
Drug: Intensified extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified extended dialysis (IED) therapy, dosed to maintain plasma urea levels <90 mg/dL (<15 mmol/L)
Study: 19218540
Drug: Standard dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysis (SED) therapy, dosed to maintain plasma urea levels between 120 and 150 mg/dL (20‐25 mmol/L)
Study: 11376910
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine 0.5 mg/kg bolus followed by 0.25 mg/kg per h (group 3)
Study: 11376910
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine 0.25 mg/kg bolus followed by 0.125 mg/kg per h (group 2)
Study: 11376910
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine 0.25 mg/kg and 0.125 mg/kg per h (group 4)
Study: 11376910
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine 0.5 mg/kg and 0.25 mg/kg per h (group 5)
Study: 7683942
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (intravenous leucovorin 200 mg/m2/day, 5-fluorouracil 550 mg/m2/day, cisplatin 20 mg/m2/day for four week cycles)
Study: 3828169
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl anaesthesia (100 micrograms/kg body weight)
Study: 26602782
Drug: Daily sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sedation interruption plus protocolized sedation (DSI + PS)
Study: 25544955
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of ketamine plus 2 mL of bupivacaine 0.5%
Study: 25544955
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of normal saline plus 2 mL of bupivacaine 0.5%
Study: 25544955
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of normal saline
Study: 22240782
Drug: P-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-containing therapy
Study: 15933509
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral antibiotics
Study: 12075761
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (100,000 IU/kg/day in three divided doses for 10 days)
Study: 7636641
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (600 mg calcium as calcium citrate malate)
Study: 7636641
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (600 mg calcium as calcium citrate malate) in black subjects
Study: 7636641
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (600 mg calcium as calcium citrate malate) based on baseline calcium intake quartiles
Study: 2651327
Drug: Oral vasodilators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vasodilators
Study: 336116
Drug: Schedule I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule I: Prednisone plus chlorambucil (CLB) given as a once-a-month dose of 0.4-0.8 mg/kg
Study: 336116
Drug: Schedule II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule II: Prednisone plus chlorambucil (CLB) given as a daily dose of 0.08 mg/kg
Study: 23860024
Drug: Naturopathic reflex
Normalized name: Cuscuta reflexa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturopathic reflex therapies (massage, Gua Sha massage, cupping, wet packs, rhythmic embrocation)
Study: 23860024
Drug: Naturopathic reflex
Normalized name: Cuscuta reflexa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturopathic reflex therapies
Study: 15526716
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) treatment
Study: 9599737
Drug: After treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: After treatment
Study: 11091828
Drug: Topical ethanol
Normalized name: ethanol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ethanol applied to the operative site for three minutes
Study: 11091828
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received the same analgesic protocol including infiltration of the operative site with ropivacaine
Study: 9372359
Drug: Allylamine preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allylamine preparations and ciclopirox olamine
Study: 1403038
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 25 mg/m2/d times three, intravenous (IV) bolus plus cisplatin (CDDP) 100 mg/m2, 24 hour infusion, every 3 weeks times six; preceded by high-dose methotrexate (HDMTX) 8 g/m2, 6-hour infusion, every 4.5 weeks times four.
Study: 1403038
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) 8 g/m2, 6-hour infusion, every 4.5 weeks times four, followed by Doxorubicin (DOX) and Cisplatin (CDDP).
Study: 31593709
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg i.v. citalopram
Study: 31593709
Drug: 11.25 mg
Normalized name: phentermine 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 mg citalopram